| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioblastoma | 88 | 2024 | 1797 | 12.220 |
Why?
|
| Brain Neoplasms | 111 | 2024 | 4849 | 10.460 |
Why?
|
| Glioma | 64 | 2024 | 1963 | 10.110 |
Why?
|
| STAT3 Transcription Factor | 23 | 2022 | 1121 | 4.610 |
Why?
|
| Immunotherapy | 38 | 2024 | 3341 | 3.150 |
Why?
|
| Immune Tolerance | 15 | 2022 | 403 | 2.810 |
Why?
|
| Macrophages | 19 | 2023 | 1304 | 2.600 |
Why?
|
| Tumor Microenvironment | 32 | 2024 | 2864 | 2.330 |
Why?
|
| T-Lymphocytes, Regulatory | 15 | 2022 | 673 | 2.320 |
Why?
|
| Microglia | 10 | 2023 | 164 | 2.320 |
Why?
|
| Tyrphostins | 8 | 2022 | 107 | 2.190 |
Why?
|
| Neoplastic Stem Cells | 17 | 2023 | 1443 | 1.640 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 6 | 2021 | 992 | 1.570 |
Why?
|
| Cancer Vaccines | 12 | 2017 | 697 | 1.550 |
Why?
|
| ErbB Receptors | 16 | 2019 | 2295 | 1.440 |
Why?
|
| Pyridines | 9 | 2022 | 1244 | 1.410 |
Why?
|
| T-Lymphocytes | 21 | 2023 | 3869 | 1.410 |
Why?
|
| Meningeal Neoplasms | 6 | 2023 | 441 | 1.340 |
Why?
|
| Central Nervous System Neoplasms | 6 | 2021 | 502 | 1.330 |
Why?
|
| Programmed Cell Death 1 Receptor | 5 | 2024 | 1048 | 1.310 |
Why?
|
| B7-H1 Antigen | 4 | 2023 | 1022 | 1.150 |
Why?
|
| Dacarbazine | 8 | 2016 | 485 | 1.140 |
Why?
|
| Cytomegalovirus Infections | 4 | 2020 | 462 | 1.120 |
Why?
|
| Melanoma, Experimental | 4 | 2011 | 368 | 1.110 |
Why?
|
| Aptamers, Nucleotide | 3 | 2022 | 62 | 1.100 |
Why?
|
| Animals | 79 | 2024 | 59536 | 1.080 |
Why?
|
| MicroRNAs | 6 | 2017 | 2947 | 1.080 |
Why?
|
| Cell Line, Tumor | 42 | 2023 | 14551 | 1.060 |
Why?
|
| Neoplasm Proteins | 6 | 2021 | 3230 | 1.050 |
Why?
|
| CD8-Positive T-Lymphocytes | 10 | 2024 | 1586 | 1.040 |
Why?
|
| Humans | 163 | 2024 | 261506 | 1.040 |
Why?
|
| Cytomegalovirus | 4 | 2020 | 482 | 0.990 |
Why?
|
| T-Lymphocyte Subsets | 6 | 2021 | 582 | 0.970 |
Why?
|
| Mice | 60 | 2023 | 34495 | 0.970 |
Why?
|
| Isocitrate Dehydrogenase | 7 | 2023 | 480 | 0.930 |
Why?
|
| Gene Expression Regulation, Neoplastic | 25 | 2022 | 8873 | 0.890 |
Why?
|
| Biomarkers, Tumor | 16 | 2018 | 10331 | 0.880 |
Why?
|
| Fibrinogen | 8 | 2023 | 205 | 0.870 |
Why?
|
| Mice, Inbred C57BL | 22 | 2023 | 6942 | 0.870 |
Why?
|
| Cancer-Associated Fibroblasts | 1 | 2024 | 107 | 0.860 |
Why?
|
| Immunosuppressive Agents | 4 | 2020 | 1375 | 0.820 |
Why?
|
| Immunotherapy, Adoptive | 4 | 2020 | 1763 | 0.810 |
Why?
|
| Drug Resistant Epilepsy | 1 | 2024 | 181 | 0.780 |
Why?
|
| Tumor Escape | 5 | 2021 | 251 | 0.770 |
Why?
|
| Tripartite Motif-Containing Protein 28 | 1 | 2020 | 32 | 0.730 |
Why?
|
| Interferon Regulatory Factor-1 | 1 | 2020 | 53 | 0.730 |
Why?
|
| Cell Communication | 2 | 2020 | 509 | 0.700 |
Why?
|
| Immunity, Innate | 3 | 2020 | 677 | 0.690 |
Why?
|
| STAT1 Transcription Factor | 1 | 2020 | 156 | 0.690 |
Why?
|
| Viral Matrix Proteins | 1 | 2020 | 201 | 0.690 |
Why?
|
| Meningioma | 4 | 2023 | 289 | 0.680 |
Why?
|
| Antigens, Neoplasm | 7 | 2020 | 1506 | 0.670 |
Why?
|
| Interleukin-13 Receptor alpha2 Subunit | 1 | 2018 | 32 | 0.640 |
Why?
|
| Osteopontin | 1 | 2018 | 148 | 0.640 |
Why?
|
| Mutation | 16 | 2023 | 15179 | 0.640 |
Why?
|
| Cell Proliferation | 18 | 2024 | 7226 | 0.600 |
Why?
|
| Nanoparticles | 2 | 2024 | 554 | 0.590 |
Why?
|
| Astrocytoma | 2 | 2018 | 321 | 0.590 |
Why?
|
| Melanoma | 6 | 2021 | 5317 | 0.580 |
Why?
|
| Signal Transduction | 18 | 2023 | 11965 | 0.580 |
Why?
|
| Gene Fusion | 1 | 2018 | 209 | 0.580 |
Why?
|
| Disease Models, Animal | 16 | 2023 | 7222 | 0.570 |
Why?
|
| Vaccines, Subunit | 4 | 2015 | 124 | 0.560 |
Why?
|
| Transfection | 2 | 2019 | 2944 | 0.550 |
Why?
|
| Astrocytes | 2 | 2020 | 368 | 0.540 |
Why?
|
| Epilepsy | 1 | 2024 | 883 | 0.540 |
Why?
|
| Antineoplastic Agents, Alkylating | 5 | 2013 | 588 | 0.530 |
Why?
|
| DNA Mismatch Repair | 1 | 2017 | 268 | 0.530 |
Why?
|
| Lymphopenia | 3 | 2021 | 199 | 0.520 |
Why?
|
| Flow Cytometry | 8 | 2015 | 3033 | 0.500 |
Why?
|
| Mice, Nude | 10 | 2020 | 4307 | 0.500 |
Why?
|
| Glioma, Subependymal | 1 | 2014 | 25 | 0.500 |
Why?
|
| Hemocyanins | 3 | 2009 | 50 | 0.500 |
Why?
|
| Precision Medicine | 4 | 2023 | 1154 | 0.480 |
Why?
|
| Adult | 40 | 2023 | 77950 | 0.480 |
Why?
|
| Antigens, CD | 5 | 2021 | 1385 | 0.470 |
Why?
|
| Female | 47 | 2023 | 141928 | 0.460 |
Why?
|
| Cerebellar Neoplasms | 1 | 2018 | 434 | 0.460 |
Why?
|
| Medulloblastoma | 1 | 2018 | 540 | 0.440 |
Why?
|
| Lipids | 1 | 2017 | 644 | 0.440 |
Why?
|
| Leukocytes, Mononuclear | 3 | 2013 | 709 | 0.440 |
Why?
|
| Drug Screening Assays, Antitumor | 1 | 2014 | 566 | 0.440 |
Why?
|
| Tissue Array Analysis | 5 | 2014 | 760 | 0.440 |
Why?
|
| Blood-Brain Barrier | 4 | 2022 | 238 | 0.430 |
Why?
|
| Central Nervous System | 6 | 2023 | 436 | 0.430 |
Why?
|
| Middle Aged | 37 | 2021 | 86204 | 0.420 |
Why?
|
| Antineoplastic Agents | 8 | 2023 | 14289 | 0.410 |
Why?
|
| Cytotoxicity, Immunologic | 3 | 2010 | 675 | 0.410 |
Why?
|
| Neoplasm Metastasis | 4 | 2018 | 5112 | 0.410 |
Why?
|
| Membrane Proteins | 1 | 2022 | 2819 | 0.410 |
Why?
|
| Aged | 33 | 2021 | 70117 | 0.410 |
Why?
|
| CTLA-4 Antigen | 1 | 2015 | 657 | 0.410 |
Why?
|
| Monocytes | 3 | 2014 | 788 | 0.400 |
Why?
|
| Chemoradiotherapy | 1 | 2020 | 1946 | 0.390 |
Why?
|
| Forkhead Transcription Factors | 3 | 2015 | 778 | 0.390 |
Why?
|
| Hypoxia | 2 | 2011 | 443 | 0.390 |
Why?
|
| Male | 40 | 2021 | 123000 | 0.380 |
Why?
|
| Chemotaxis, Leukocyte | 2 | 2010 | 157 | 0.380 |
Why?
|
| Xenograft Model Antitumor Assays | 9 | 2023 | 3821 | 0.380 |
Why?
|
| Lymphocyte Activation | 7 | 2016 | 1688 | 0.380 |
Why?
|
| Interferons | 2 | 2022 | 291 | 0.370 |
Why?
|
| 5'-Nucleotidase | 2 | 2020 | 61 | 0.360 |
Why?
|
| Immunologic Memory | 4 | 2023 | 374 | 0.360 |
Why?
|
| Prognosis | 21 | 2020 | 21713 | 0.360 |
Why?
|
| RNA-Binding Proteins | 4 | 2021 | 984 | 0.360 |
Why?
|
| Dendritic Cells | 3 | 2021 | 1085 | 0.350 |
Why?
|
| Chemokines | 2 | 2010 | 314 | 0.350 |
Why?
|
| Dogs | 3 | 2021 | 1155 | 0.350 |
Why?
|
| Standard of Care | 1 | 2010 | 243 | 0.340 |
Why?
|
| Phosphorylation | 9 | 2021 | 4804 | 0.340 |
Why?
|
| Antibodies, Neoplasm | 2 | 2008 | 259 | 0.340 |
Why?
|
| Antigen-Presenting Cells | 3 | 2024 | 284 | 0.340 |
Why?
|
| Vimentin | 3 | 2018 | 253 | 0.330 |
Why?
|
| Aged, 80 and over | 19 | 2021 | 29902 | 0.310 |
Why?
|
| Aging | 1 | 2016 | 1582 | 0.310 |
Why?
|
| Myeloid Cells | 5 | 2022 | 269 | 0.310 |
Why?
|
| Immunohistochemistry | 10 | 2018 | 7548 | 0.310 |
Why?
|
| Topotecan | 1 | 2008 | 239 | 0.310 |
Why?
|
| Macrophage Activation | 2 | 2020 | 148 | 0.290 |
Why?
|
| DNA Methylation | 7 | 2023 | 2669 | 0.290 |
Why?
|
| Immune System | 3 | 2024 | 279 | 0.290 |
Why?
|
| Cell Lineage | 3 | 2018 | 668 | 0.280 |
Why?
|
| Cytokines | 5 | 2014 | 2809 | 0.280 |
Why?
|
| Cytochrome P-450 Enzyme System | 1 | 2007 | 200 | 0.280 |
Why?
|
| Adolescent | 16 | 2021 | 31252 | 0.280 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2018 | 6207 | 0.270 |
Why?
|
| Lymphocyte Depletion | 2 | 2020 | 264 | 0.270 |
Why?
|
| Interferon-alpha | 1 | 2010 | 889 | 0.270 |
Why?
|
| Disease Progression | 11 | 2023 | 6682 | 0.270 |
Why?
|
| RNA, Messenger | 6 | 2021 | 6150 | 0.260 |
Why?
|
| Gene Expression | 2 | 2018 | 3570 | 0.260 |
Why?
|
| Child, Preschool | 8 | 2021 | 16273 | 0.260 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2012 | 1248 | 0.260 |
Why?
|
| Mice, Transgenic | 8 | 2021 | 4143 | 0.250 |
Why?
|
| Child | 11 | 2021 | 29154 | 0.250 |
Why?
|
| Biomarkers | 4 | 2023 | 5047 | 0.250 |
Why?
|
| Ultrasonic Waves | 2 | 2021 | 7 | 0.250 |
Why?
|
| Cohort Studies | 9 | 2018 | 9244 | 0.250 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 5 | 2010 | 1489 | 0.250 |
Why?
|
| Molecular Targeted Therapy | 4 | 2019 | 2330 | 0.250 |
Why?
|
| Cyclophosphamide | 1 | 2011 | 3001 | 0.240 |
Why?
|
| Young Adult | 13 | 2021 | 21445 | 0.240 |
Why?
|
| Clinical Trials as Topic | 7 | 2018 | 3719 | 0.240 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2014 | 80 | 0.230 |
Why?
|
| Immunologic Factors | 4 | 2015 | 649 | 0.230 |
Why?
|
| Brain | 6 | 2023 | 4113 | 0.230 |
Why?
|
| Nanostructures | 1 | 2024 | 94 | 0.230 |
Why?
|
| Peptides | 1 | 2009 | 1479 | 0.230 |
Why?
|
| Breast Neoplasms | 3 | 2023 | 15694 | 0.220 |
Why?
|
| Treatment Outcome | 15 | 2021 | 32848 | 0.220 |
Why?
|
| Neoplasm Grading | 4 | 2021 | 1742 | 0.220 |
Why?
|
| Phenotype | 10 | 2022 | 6295 | 0.220 |
Why?
|
| Oligodendroglioma | 2 | 2018 | 106 | 0.220 |
Why?
|
| Myelin Sheath | 2 | 2021 | 149 | 0.220 |
Why?
|
| Nucleotidyltransferases | 1 | 2022 | 82 | 0.220 |
Why?
|
| Neoplasms | 5 | 2021 | 15193 | 0.210 |
Why?
|
| Biological Transport | 1 | 2024 | 597 | 0.210 |
Why?
|
| CLOCK Proteins | 1 | 2022 | 35 | 0.210 |
Why?
|
| Circadian Clocks | 1 | 2023 | 66 | 0.210 |
Why?
|
| Tumor Cells, Cultured | 3 | 2017 | 5395 | 0.210 |
Why?
|
| Survival Rate | 9 | 2019 | 12221 | 0.210 |
Why?
|
| Cells, Cultured | 6 | 2020 | 5637 | 0.210 |
Why?
|
| CD11c Antigen | 1 | 2021 | 55 | 0.200 |
Why?
|
| Antigens, Differentiation, Myelomonocytic | 1 | 2021 | 134 | 0.200 |
Why?
|
| Gliosarcoma | 1 | 2021 | 29 | 0.200 |
Why?
|
| Collagen | 2 | 2024 | 752 | 0.200 |
Why?
|
| Killer Cells, Natural | 2 | 2021 | 904 | 0.200 |
Why?
|
| Myeloid-Derived Suppressor Cells | 1 | 2022 | 100 | 0.200 |
Why?
|
| Injections, Intralesional | 1 | 2021 | 164 | 0.200 |
Why?
|
| Antibiotics, Antineoplastic | 1 | 2005 | 726 | 0.200 |
Why?
|
| Demyelinating Autoimmune Diseases, CNS | 1 | 2021 | 7 | 0.200 |
Why?
|
| Chemokine CXCL2 | 1 | 2021 | 35 | 0.200 |
Why?
|
| Chemokine CXCL1 | 1 | 2021 | 60 | 0.200 |
Why?
|
| Immunoenzyme Techniques | 2 | 2015 | 1165 | 0.190 |
Why?
|
| Receptor, Adenosine A2A | 1 | 2020 | 27 | 0.190 |
Why?
|
| Methyltransferases | 1 | 2022 | 148 | 0.190 |
Why?
|
| Chemokines, CXC | 1 | 2021 | 117 | 0.190 |
Why?
|
| Antibodies, Monoclonal | 6 | 2018 | 4367 | 0.190 |
Why?
|
| Apyrase | 1 | 2020 | 44 | 0.190 |
Why?
|
| PPAR-beta | 1 | 2020 | 14 | 0.190 |
Why?
|
| RNA Stability | 1 | 2021 | 125 | 0.190 |
Why?
|
| Sirolimus | 1 | 2005 | 814 | 0.190 |
Why?
|
| Phagocytosis | 2 | 2021 | 260 | 0.180 |
Why?
|
| Receptors, Cell Surface | 2 | 2021 | 862 | 0.180 |
Why?
|
| Demyelinating Diseases | 1 | 2020 | 77 | 0.180 |
Why?
|
| Photosensitizing Agents | 1 | 2020 | 71 | 0.180 |
Why?
|
| Apoptosis | 6 | 2016 | 7591 | 0.180 |
Why?
|
| Integrins | 1 | 2021 | 262 | 0.180 |
Why?
|
| Leukapheresis | 1 | 2020 | 152 | 0.180 |
Why?
|
| Immune Evasion | 1 | 2020 | 73 | 0.180 |
Why?
|
| Catalase | 2 | 1990 | 70 | 0.180 |
Why?
|
| Cell- and Tissue-Based Therapy | 2 | 2020 | 406 | 0.180 |
Why?
|
| DNA-Binding Proteins | 2 | 2020 | 4821 | 0.170 |
Why?
|
| Antigen Presentation | 1 | 2020 | 272 | 0.170 |
Why?
|
| Integrin alpha Chains | 1 | 2019 | 28 | 0.170 |
Why?
|
| Receptors, Vitronectin | 1 | 2018 | 24 | 0.170 |
Why?
|
| Oncolytic Virotherapy | 1 | 2022 | 280 | 0.170 |
Why?
|
| Antigenic Variation | 1 | 2018 | 38 | 0.160 |
Why?
|
| Vascular Endothelial Growth Factor A | 4 | 2014 | 1533 | 0.160 |
Why?
|
| Venous Thromboembolism | 1 | 2023 | 335 | 0.160 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 2 | 2008 | 102 | 0.160 |
Why?
|
| Infratentorial Neoplasms | 1 | 2018 | 45 | 0.160 |
Why?
|
| Cell Movement | 4 | 2021 | 2466 | 0.160 |
Why?
|
| Cell Separation | 2 | 2010 | 612 | 0.160 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 6 | 2018 | 15862 | 0.160 |
Why?
|
| Neovascularization, Pathologic | 3 | 2012 | 1547 | 0.160 |
Why?
|
| Mice, Inbred BALB C | 5 | 2015 | 2314 | 0.150 |
Why?
|
| Autophagy | 2 | 2023 | 927 | 0.150 |
Why?
|
| Peptide Fragments | 1 | 2003 | 1271 | 0.150 |
Why?
|
| RNA, Small Interfering | 2 | 2022 | 2216 | 0.150 |
Why?
|
| Skin Neoplasms | 2 | 2012 | 4654 | 0.150 |
Why?
|
| Mice, Knockout | 4 | 2020 | 5710 | 0.150 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2020 | 3251 | 0.150 |
Why?
|
| DNA, Neoplasm | 1 | 2002 | 1910 | 0.150 |
Why?
|
| Lipid Metabolism | 1 | 2020 | 483 | 0.140 |
Why?
|
| Immunity, Cellular | 1 | 2018 | 419 | 0.140 |
Why?
|
| Neurosurgical Procedures | 2 | 2020 | 609 | 0.140 |
Why?
|
| Endosomes | 1 | 2016 | 109 | 0.140 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 677 | 0.140 |
Why?
|
| Metabolomics | 2 | 2018 | 478 | 0.140 |
Why?
|
| CD4-Positive T-Lymphocytes | 3 | 2019 | 1033 | 0.140 |
Why?
|
| Gene Knockdown Techniques | 1 | 2018 | 1077 | 0.130 |
Why?
|
| Transforming Growth Factor beta | 1 | 2021 | 1130 | 0.130 |
Why?
|
| Trastuzumab | 1 | 2018 | 696 | 0.130 |
Why?
|
| Transplantation, Autologous | 1 | 2020 | 1914 | 0.130 |
Why?
|
| Receptors, Antigen | 1 | 2015 | 76 | 0.130 |
Why?
|
| Chromosome Aberrations | 1 | 2002 | 1960 | 0.130 |
Why?
|
| Cell Differentiation | 5 | 2019 | 4078 | 0.130 |
Why?
|
| Up-Regulation | 2 | 2014 | 2450 | 0.130 |
Why?
|
| Neural Stem Cells | 1 | 2016 | 181 | 0.130 |
Why?
|
| Blotting, Western | 4 | 2012 | 3536 | 0.130 |
Why?
|
| Neoplasm Transplantation | 2 | 2021 | 1519 | 0.130 |
Why?
|
| Watchful Waiting | 1 | 2017 | 289 | 0.130 |
Why?
|
| Cytotoxicity Tests, Immunologic | 1 | 2014 | 84 | 0.130 |
Why?
|
| Lymphoma, Mantle-Cell | 1 | 2020 | 713 | 0.130 |
Why?
|
| Dose-Response Relationship, Drug | 3 | 2014 | 4938 | 0.130 |
Why?
|
| TOR Serine-Threonine Kinases | 2 | 2020 | 1546 | 0.130 |
Why?
|
| Platelet-Derived Growth Factor | 1 | 2015 | 157 | 0.120 |
Why?
|
| Colony-Forming Units Assay | 1 | 2014 | 249 | 0.120 |
Why?
|
| Neural Cell Adhesion Molecules | 2 | 2005 | 55 | 0.120 |
Why?
|
| Fibrin | 1 | 2014 | 82 | 0.120 |
Why?
|
| Polymerase Chain Reaction | 2 | 2015 | 3203 | 0.120 |
Why?
|
| Lysosomes | 1 | 2016 | 347 | 0.120 |
Why?
|
| Matrix Metalloproteinase 2 | 2 | 2005 | 256 | 0.120 |
Why?
|
| Tumor Necrosis Factor Receptor Superfamily, Member 9 | 1 | 2014 | 69 | 0.120 |
Why?
|
| Magnetic Resonance Spectroscopy | 1 | 2016 | 624 | 0.120 |
Why?
|
| STAT5 Transcription Factor | 1 | 2014 | 214 | 0.120 |
Why?
|
| Cell Survival | 3 | 2021 | 3045 | 0.110 |
Why?
|
| B-Cell Activating Factor | 1 | 2013 | 25 | 0.110 |
Why?
|
| Real-Time Polymerase Chain Reaction | 2 | 2014 | 1217 | 0.110 |
Why?
|
| Research Design | 2 | 2018 | 1544 | 0.110 |
Why?
|
| Escherichia coli | 2 | 1990 | 1203 | 0.110 |
Why?
|
| Glycoproteins | 4 | 2023 | 747 | 0.110 |
Why?
|
| Cadherins | 1 | 2016 | 660 | 0.110 |
Why?
|
| Seizures | 2 | 2023 | 989 | 0.110 |
Why?
|
| Nestin | 1 | 2012 | 42 | 0.110 |
Why?
|
| Phenytoin | 1 | 2013 | 71 | 0.110 |
Why?
|
| Transforming Growth Factor beta1 | 1 | 2014 | 292 | 0.110 |
Why?
|
| Intermediate Filament Proteins | 1 | 2012 | 81 | 0.110 |
Why?
|
| Retrospective Studies | 8 | 2021 | 37905 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 2 | 2019 | 2359 | 0.110 |
Why?
|
| Drug Synergism | 2 | 2018 | 1313 | 0.100 |
Why?
|
| Receptors, Antigen, T-Cell | 2 | 2016 | 1146 | 0.100 |
Why?
|
| Neoplasm Invasiveness | 4 | 2016 | 3981 | 0.100 |
Why?
|
| Administration, Metronomic | 1 | 2011 | 15 | 0.100 |
Why?
|
| RNA, Long Noncoding | 1 | 2017 | 598 | 0.100 |
Why?
|
| 3' Untranslated Regions | 1 | 2013 | 343 | 0.100 |
Why?
|
| Interleukin-10 | 2 | 2011 | 478 | 0.100 |
Why?
|
| Cell Hypoxia | 1 | 2012 | 328 | 0.100 |
Why?
|
| Symbiosis | 2 | 2022 | 77 | 0.100 |
Why?
|
| Mesoderm | 1 | 2013 | 404 | 0.100 |
Why?
|
| Craniotomy | 2 | 2013 | 304 | 0.100 |
Why?
|
| NF-kappa B | 2 | 2019 | 1549 | 0.100 |
Why?
|
| O(6)-Methylguanine-DNA Methyltransferase | 1 | 2010 | 69 | 0.100 |
Why?
|
| Hypersensitivity, Delayed | 1 | 2010 | 104 | 0.100 |
Why?
|
| Drug Interactions | 1 | 2012 | 553 | 0.100 |
Why?
|
| Chemotactic Factors | 1 | 2010 | 42 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 5 | 2023 | 10035 | 0.100 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2016 | 2232 | 0.100 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2018 | 2291 | 0.090 |
Why?
|
| Neoplasms, Experimental | 1 | 2014 | 750 | 0.090 |
Why?
|
| HL-60 Cells | 1 | 2011 | 302 | 0.090 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2023 | 2027 | 0.090 |
Why?
|
| Tumor Suppressor Protein p53 | 3 | 2020 | 3552 | 0.090 |
Why?
|
| Transcription Factors | 1 | 2005 | 5270 | 0.090 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 2283 | 0.090 |
Why?
|
| Proton Therapy | 1 | 2021 | 1577 | 0.090 |
Why?
|
| Gene Expression Regulation, Viral | 1 | 2011 | 187 | 0.090 |
Why?
|
| Follow-Up Studies | 5 | 2019 | 14889 | 0.090 |
Why?
|
| Cyanoacrylates | 1 | 2010 | 41 | 0.090 |
Why?
|
| Genes, bcl-2 | 1 | 2010 | 166 | 0.090 |
Why?
|
| Radiotherapy, Intensity-Modulated | 1 | 2021 | 2104 | 0.090 |
Why?
|
| Radiation Tolerance | 1 | 2013 | 629 | 0.090 |
Why?
|
| Gene Expression Profiling | 4 | 2017 | 5159 | 0.090 |
Why?
|
| Algorithms | 3 | 2019 | 3890 | 0.090 |
Why?
|
| Quality of Life | 1 | 2024 | 4532 | 0.090 |
Why?
|
| Survival Analysis | 5 | 2019 | 9180 | 0.090 |
Why?
|
| Disease-Free Survival | 6 | 2018 | 10001 | 0.090 |
Why?
|
| Anticonvulsants | 1 | 2013 | 431 | 0.090 |
Why?
|
| Neoplasm Staging | 3 | 2015 | 13658 | 0.090 |
Why?
|
| Immunity | 3 | 2023 | 342 | 0.090 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 2 | 2023 | 650 | 0.090 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 1 | 2011 | 376 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2014 | 2074 | 0.080 |
Why?
|
| Immunoglobulin E | 1 | 2009 | 163 | 0.080 |
Why?
|
| Binding Sites | 1 | 2013 | 2171 | 0.080 |
Why?
|
| Base Sequence | 2 | 2013 | 4917 | 0.080 |
Why?
|
| Tumor Suppressor Proteins | 3 | 2023 | 1823 | 0.080 |
Why?
|
| Bevacizumab | 1 | 2012 | 938 | 0.080 |
Why?
|
| Perioperative Care | 1 | 2013 | 451 | 0.080 |
Why?
|
| Mutant Proteins | 1 | 2009 | 234 | 0.080 |
Why?
|
| RNA Interference | 1 | 2013 | 1408 | 0.080 |
Why?
|
| Age Factors | 2 | 2016 | 5377 | 0.080 |
Why?
|
| Antibody-Dependent Cell Cytotoxicity | 1 | 2008 | 84 | 0.080 |
Why?
|
| Receptor, Fibroblast Growth Factor, Type 3 | 1 | 2008 | 62 | 0.080 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2018 | 1249 | 0.080 |
Why?
|
| Carcinogenesis | 3 | 2021 | 1026 | 0.080 |
Why?
|
| Ligands | 2 | 2023 | 995 | 0.080 |
Why?
|
| Immunoblotting | 1 | 2010 | 886 | 0.080 |
Why?
|
| Combined Modality Therapy | 4 | 2019 | 8865 | 0.080 |
Why?
|
| Ultraviolet Rays | 1 | 1990 | 575 | 0.080 |
Why?
|
| Protons | 2 | 2021 | 473 | 0.080 |
Why?
|
| CD146 Antigen | 2 | 2005 | 57 | 0.080 |
Why?
|
| Nerve Tissue Proteins | 2 | 2013 | 1491 | 0.080 |
Why?
|
| Wakefulness | 1 | 2009 | 150 | 0.080 |
Why?
|
| DNA Modification Methylases | 2 | 2023 | 172 | 0.080 |
Why?
|
| Syk Kinase | 1 | 2007 | 56 | 0.080 |
Why?
|
| B7-2 Antigen | 1 | 2007 | 55 | 0.080 |
Why?
|
| Radiosurgery | 1 | 2017 | 1330 | 0.080 |
Why?
|
| Fas Ligand Protein | 1 | 2008 | 150 | 0.080 |
Why?
|
| Inosine | 1 | 2007 | 39 | 0.080 |
Why?
|
| Chemokine CCL22 | 1 | 2007 | 13 | 0.080 |
Why?
|
| Heterografts | 2 | 2021 | 733 | 0.080 |
Why?
|
| Protein Processing, Post-Translational | 1 | 2012 | 803 | 0.080 |
Why?
|
| B7-1 Antigen | 1 | 2007 | 88 | 0.080 |
Why?
|
| Cytochrome P-450 CYP1B1 | 1 | 2007 | 42 | 0.080 |
Why?
|
| Transplantation, Heterologous | 1 | 2010 | 1082 | 0.080 |
Why?
|
| Quinazolines | 1 | 2012 | 923 | 0.080 |
Why?
|
| Receptors, CCR4 | 1 | 2007 | 34 | 0.080 |
Why?
|
| CD3 Complex | 1 | 2008 | 314 | 0.080 |
Why?
|
| Antibody Formation | 1 | 2008 | 383 | 0.080 |
Why?
|
| Receptors, CCR2 | 1 | 2007 | 41 | 0.080 |
Why?
|
| fas Receptor | 1 | 2008 | 185 | 0.070 |
Why?
|
| Aryl Hydrocarbon Hydroxylases | 1 | 2007 | 78 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 2 | 2008 | 657 | 0.070 |
Why?
|
| DNA Repair Enzymes | 2 | 2023 | 237 | 0.070 |
Why?
|
| RNA Editing | 1 | 2007 | 92 | 0.070 |
Why?
|
| Carmustine | 1 | 2007 | 214 | 0.070 |
Why?
|
| Hypersensitivity | 1 | 2009 | 216 | 0.070 |
Why?
|
| Antibody-Producing Cells | 1 | 2006 | 15 | 0.070 |
Why?
|
| Inflammation | 2 | 2014 | 2522 | 0.070 |
Why?
|
| Language | 1 | 2009 | 309 | 0.070 |
Why?
|
| Chemokine CCL2 | 1 | 2007 | 203 | 0.070 |
Why?
|
| Epithelial-Mesenchymal Transition | 2 | 2022 | 973 | 0.070 |
Why?
|
| Pyrimidines | 2 | 2012 | 3518 | 0.070 |
Why?
|
| Liver Neoplasms | 1 | 2023 | 4557 | 0.070 |
Why?
|
| Time Factors | 4 | 2017 | 12926 | 0.070 |
Why?
|
| Cell Culture Techniques | 1 | 2009 | 598 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 2 | 2016 | 986 | 0.070 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2010 | 3890 | 0.070 |
Why?
|
| Adenosine | 1 | 2007 | 289 | 0.070 |
Why?
|
| Interferon-gamma | 2 | 2008 | 1144 | 0.060 |
Why?
|
| Cerebral Cortex | 1 | 2009 | 621 | 0.060 |
Why?
|
| Cytoplasm | 1 | 2007 | 652 | 0.060 |
Why?
|
| Transcription Factor AP-2 | 1 | 2005 | 79 | 0.060 |
Why?
|
| Genome, Human | 1 | 2013 | 1869 | 0.060 |
Why?
|
| Iatrogenic Disease | 1 | 2005 | 183 | 0.060 |
Why?
|
| Phosphoproteins | 1 | 2010 | 1152 | 0.060 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 2 | 2021 | 622 | 0.060 |
Why?
|
| Amino Acid Motifs | 1 | 2005 | 392 | 0.060 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2019 | 7702 | 0.060 |
Why?
|
| Granzymes | 1 | 2024 | 91 | 0.060 |
Why?
|
| Autoimmunity | 1 | 2005 | 263 | 0.060 |
Why?
|
| Phosphoric Monoester Hydrolases | 1 | 2005 | 243 | 0.060 |
Why?
|
| Pyrazoles | 1 | 2012 | 1471 | 0.060 |
Why?
|
| Mitogen-Activated Protein Kinases | 1 | 2006 | 639 | 0.060 |
Why?
|
| Matrix Metalloproteinase 9 | 1 | 2005 | 360 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor beta | 1 | 2004 | 153 | 0.060 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2005 | 528 | 0.060 |
Why?
|
| Nanotechnology | 1 | 2024 | 137 | 0.060 |
Why?
|
| Mice, Inbred C3H | 1 | 2003 | 385 | 0.060 |
Why?
|
| Receptor, Platelet-Derived Growth Factor alpha | 1 | 2004 | 134 | 0.060 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 4988 | 0.060 |
Why?
|
| Lung Neoplasms | 2 | 2022 | 11538 | 0.060 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2009 | 2508 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2005 | 479 | 0.050 |
Why?
|
| ARNTL Transcription Factors | 1 | 2022 | 57 | 0.050 |
Why?
|
| Incidence | 2 | 2013 | 5673 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2002 | 127 | 0.050 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2022 | 49 | 0.050 |
Why?
|
| Checkpoint Kinase 1 | 1 | 2023 | 174 | 0.050 |
Why?
|
| Tumor Burden | 2 | 2019 | 1987 | 0.050 |
Why?
|
| Nucleic Acid Hybridization | 1 | 2002 | 542 | 0.050 |
Why?
|
| Risk Factors | 3 | 2019 | 17523 | 0.050 |
Why?
|
| Mice, SCID | 2 | 2016 | 1869 | 0.050 |
Why?
|
| Intracellular Signaling Peptides and Proteins | 1 | 2007 | 1265 | 0.050 |
Why?
|
| Endoplasmic Reticulum Stress | 1 | 2023 | 204 | 0.050 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 11 | 1 | 2021 | 59 | 0.050 |
Why?
|
| Spleen | 1 | 2003 | 676 | 0.050 |
Why?
|
| Epigenesis, Genetic | 2 | 2022 | 1399 | 0.050 |
Why?
|
| Hedgehog Proteins | 1 | 2023 | 424 | 0.050 |
Why?
|
| Phagosomes | 1 | 2021 | 72 | 0.050 |
Why?
|
| CD36 Antigens | 1 | 2021 | 53 | 0.050 |
Why?
|
| Computational Biology | 3 | 2016 | 1271 | 0.050 |
Why?
|
| Epitopes | 2 | 2015 | 685 | 0.050 |
Why?
|
| Radiotherapy | 1 | 2007 | 1824 | 0.050 |
Why?
|
| Neurofibromin 1 | 1 | 2020 | 85 | 0.050 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2007 | 1756 | 0.040 |
Why?
|
| Oligodendroglia | 1 | 2020 | 96 | 0.040 |
Why?
|
| Oncogenes | 1 | 2023 | 673 | 0.040 |
Why?
|
| B-Lymphocytes | 1 | 2005 | 1294 | 0.040 |
Why?
|
| Aspirin | 1 | 2023 | 455 | 0.040 |
Why?
|
| GPI-Linked Proteins | 1 | 2019 | 223 | 0.040 |
Why?
|
| Membrane Glycoproteins | 1 | 2003 | 1073 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 2 | 2017 | 2231 | 0.040 |
Why?
|
| STAT Transcription Factors | 1 | 2019 | 79 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2006 | 2054 | 0.040 |
Why?
|
| Transcriptome | 2 | 2020 | 1859 | 0.040 |
Why?
|
| SELEX Aptamer Technique | 1 | 2018 | 5 | 0.040 |
Why?
|
| Kynurenic Acid | 1 | 2018 | 26 | 0.040 |
Why?
|
| Lymphocytes | 1 | 2003 | 1234 | 0.040 |
Why?
|
| Radiography | 1 | 2002 | 1904 | 0.040 |
Why?
|
| Analysis of Variance | 2 | 2015 | 2307 | 0.040 |
Why?
|
| DNA, Single-Stranded | 1 | 2018 | 106 | 0.040 |
Why?
|
| Axons | 1 | 2021 | 403 | 0.040 |
Why?
|
| Methionine | 1 | 2018 | 159 | 0.040 |
Why?
|
| MAP Kinase Signaling System | 1 | 2021 | 848 | 0.040 |
Why?
|
| p38 Mitogen-Activated Protein Kinases | 1 | 2019 | 334 | 0.040 |
Why?
|
| Photons | 1 | 2021 | 507 | 0.040 |
Why?
|
| Chitinase-3-Like Protein 1 | 2 | 2007 | 18 | 0.040 |
Why?
|
| Neuroglia | 1 | 2019 | 223 | 0.040 |
Why?
|
| Anticoagulants | 1 | 2023 | 787 | 0.040 |
Why?
|
| Fatty Acids | 1 | 2020 | 448 | 0.040 |
Why?
|
| Diagnosis, Differential | 2 | 2005 | 4744 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2023 | 1048 | 0.040 |
Why?
|
| Lectins | 2 | 2007 | 151 | 0.040 |
Why?
|
| Prospective Studies | 3 | 2021 | 12873 | 0.040 |
Why?
|
| Adipokines | 2 | 2007 | 96 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2018 | 700 | 0.040 |
Why?
|
| Single-Blind Method | 1 | 2017 | 409 | 0.030 |
Why?
|
| Genotype | 2 | 2017 | 4109 | 0.030 |
Why?
|
| T-Cell Antigen Receptor Specificity | 1 | 2016 | 107 | 0.030 |
Why?
|
| Stem Cell Niche | 1 | 2016 | 94 | 0.030 |
Why?
|
| In Situ Hybridization | 1 | 2018 | 1037 | 0.030 |
Why?
|
| Predictive Value of Tests | 3 | 2010 | 4892 | 0.030 |
Why?
|
| Spheroids, Cellular | 1 | 2016 | 222 | 0.030 |
Why?
|
| Cell Cycle Proteins | 1 | 2005 | 2045 | 0.030 |
Why?
|
| Cell Cycle Checkpoints | 1 | 2017 | 278 | 0.030 |
Why?
|
| Caspase 3 | 1 | 2016 | 471 | 0.030 |
Why?
|
| Metabolome | 1 | 2018 | 344 | 0.030 |
Why?
|
| Metastasectomy | 1 | 2017 | 200 | 0.030 |
Why?
|
| Costimulatory and Inhibitory T-Cell Receptors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Piperazines | 1 | 2004 | 2101 | 0.030 |
Why?
|
| Forkhead Box Protein M1 | 1 | 2015 | 113 | 0.030 |
Why?
|
| Arginine | 1 | 2018 | 500 | 0.030 |
Why?
|
| Coculture Techniques | 1 | 2016 | 626 | 0.030 |
Why?
|
| Proteolysis | 1 | 2016 | 370 | 0.030 |
Why?
|
| Carcinogenicity Tests | 1 | 2014 | 70 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2016 | 288 | 0.030 |
Why?
|
| DNA Copy Number Variations | 1 | 2021 | 1516 | 0.030 |
Why?
|
| Exome | 1 | 2020 | 1239 | 0.030 |
Why?
|
| Oligodendrocyte Transcription Factor 2 | 1 | 2013 | 25 | 0.030 |
Why?
|
| Cetuximab | 1 | 2015 | 472 | 0.030 |
Why?
|
| Aurora Kinase A | 1 | 2014 | 202 | 0.030 |
Why?
|
| Stem Cells | 1 | 2020 | 1213 | 0.030 |
Why?
|
| Blood Coagulation | 1 | 2014 | 185 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2020 | 1863 | 0.030 |
Why?
|
| Radiotherapy Dosage | 1 | 2021 | 3842 | 0.030 |
Why?
|
| Vaccination | 2 | 2010 | 1123 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2015 | 905 | 0.030 |
Why?
|
| Supratentorial Neoplasms | 1 | 2013 | 78 | 0.030 |
Why?
|
| Antibody Specificity | 1 | 2013 | 334 | 0.030 |
Why?
|
| Ipilimumab | 1 | 2017 | 710 | 0.030 |
Why?
|
| Hyaluronan Receptors | 1 | 2013 | 249 | 0.030 |
Why?
|
| Cyclin D1 | 1 | 2014 | 576 | 0.030 |
Why?
|
| Medical Oncology | 1 | 2021 | 1423 | 0.030 |
Why?
|
| Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2012 | 157 | 0.030 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2015 | 565 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell, alpha-beta | 1 | 1992 | 173 | 0.030 |
Why?
|
| Chickens | 1 | 2012 | 523 | 0.030 |
Why?
|
| Interleukin-4 | 1 | 1992 | 284 | 0.030 |
Why?
|
| T-Lymphocytes, Helper-Inducer | 1 | 1992 | 212 | 0.020 |
Why?
|
| Injections, Intradermal | 1 | 2010 | 58 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 1053 | 0.020 |
Why?
|
| Antigens, Differentiation, T-Lymphocyte | 1 | 1990 | 167 | 0.020 |
Why?
|
| Cell Membrane Permeability | 1 | 1990 | 122 | 0.020 |
Why?
|
| CD4 Antigens | 1 | 1990 | 170 | 0.020 |
Why?
|
| International Cooperation | 1 | 2012 | 323 | 0.020 |
Why?
|
| Sequence Analysis, DNA | 1 | 2018 | 2483 | 0.020 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.020 |
Why?
|
| Sample Size | 1 | 2010 | 202 | 0.020 |
Why?
|
| San Francisco | 1 | 2009 | 19 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2012 | 1062 | 0.020 |
Why?
|
| Antibodies | 1 | 2013 | 838 | 0.020 |
Why?
|
| Cell Division | 2 | 2004 | 2489 | 0.020 |
Why?
|
| Thymus Gland | 1 | 1990 | 294 | 0.020 |
Why?
|
| Recurrence | 1 | 2017 | 4758 | 0.020 |
Why?
|
| Spheroplasts | 1 | 1988 | 4 | 0.020 |
Why?
|
| Neurologic Examination | 1 | 2009 | 245 | 0.020 |
Why?
|
| Cell Fractionation | 1 | 1988 | 68 | 0.020 |
Why?
|
| Plasmids | 1 | 1990 | 837 | 0.020 |
Why?
|
| Bayes Theorem | 1 | 2013 | 1021 | 0.020 |
Why?
|
| Animals, Newborn | 1 | 2012 | 1338 | 0.020 |
Why?
|
| Electric Stimulation | 1 | 2009 | 426 | 0.020 |
Why?
|
| Multigene Family | 1 | 2009 | 425 | 0.020 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2013 | 1538 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2015 | 3101 | 0.020 |
Why?
|
| Adenosine Deaminase | 1 | 2007 | 94 | 0.020 |
Why?
|
| Genes, Bacterial | 1 | 1988 | 236 | 0.020 |
Why?
|
| Kinetics | 1 | 1990 | 2049 | 0.020 |
Why?
|
| Alu Elements | 1 | 2007 | 88 | 0.020 |
Why?
|
| Genes | 1 | 1988 | 491 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2009 | 665 | 0.020 |
Why?
|
| RNA Precursors | 1 | 2007 | 137 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2009 | 1323 | 0.020 |
Why?
|
| Ribosomal Protein S6 Kinases, 70-kDa | 1 | 2006 | 131 | 0.020 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2012 | 3639 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2008 | 467 | 0.020 |
Why?
|
| RNA, Untranslated | 1 | 2007 | 237 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 1 | 2017 | 4549 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2012 | 1682 | 0.020 |
Why?
|
| Brain Mapping | 1 | 2009 | 644 | 0.020 |
Why?
|
| Risk Assessment | 2 | 2009 | 6869 | 0.020 |
Why?
|
| Cell Membrane | 1 | 1988 | 850 | 0.020 |
Why?
|
| Nervous System Diseases | 1 | 2009 | 500 | 0.020 |
Why?
|
| Drug Administration Schedule | 1 | 2010 | 3472 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2018 | 5178 | 0.020 |
Why?
|
| Odds Ratio | 1 | 2009 | 2316 | 0.020 |
Why?
|
| Molecular Sequence Data | 2 | 2007 | 6089 | 0.010 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2017 | 5539 | 0.010 |
Why?
|
| Regression Analysis | 1 | 2007 | 1546 | 0.010 |
Why?
|
| Laminin | 1 | 2003 | 194 | 0.010 |
Why?
|
| Proteoglycans | 1 | 2003 | 259 | 0.010 |
Why?
|
| Health Status | 1 | 2005 | 590 | 0.010 |
Why?
|
| Protein Kinases | 1 | 2006 | 874 | 0.010 |
Why?
|
| Drug Combinations | 1 | 2003 | 621 | 0.010 |
Why?
|
| Logistic Models | 1 | 2009 | 3441 | 0.010 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 2403 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2003 | 1008 | 0.010 |
Why?
|
| Bone and Bones | 1 | 2003 | 619 | 0.010 |
Why?
|
| Immunoglobulin G | 1 | 2003 | 1021 | 0.010 |
Why?
|
| Multivariate Analysis | 1 | 2007 | 4298 | 0.010 |
Why?
|
| Imatinib Mesylate | 1 | 2004 | 1665 | 0.010 |
Why?
|
| Case-Control Studies | 1 | 2009 | 6100 | 0.010 |
Why?
|
| Endothelium, Vascular | 1 | 2003 | 891 | 0.010 |
Why?
|
| Benzamides | 1 | 2004 | 1832 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2009 | 5687 | 0.010 |
Why?
|
| Lymphoma | 1 | 2005 | 1467 | 0.010 |
Why?
|
| Osteosarcoma | 1 | 2003 | 929 | 0.010 |
Why?
|
| Sarcoma | 1 | 2003 | 1725 | 0.010 |
Why?
|
| Ovalbumin | 1 | 1990 | 254 | 0.010 |
Why?
|
| CD8 Antigens | 1 | 1990 | 170 | 0.010 |
Why?
|
| Immunization | 1 | 1992 | 397 | 0.010 |
Why?
|
| Microscopy, Electron | 1 | 1990 | 600 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 1990 | 4233 | 0.000 |
Why?
|